Database Login

Preclinical Services

Our Focus is Anticancer Therapeutics

Just as there is no such thing as one disease called cancer, there can be no standard approach to anticancer therapeutics development. Bringing certainty to preclinical development decisions requires a deep understanding of cancer and all its complexities—and the ability to translate chemotherapeutic, targeted and combinatorial therapeutic approaches into study design and execution.

At Certis, our scientific team works alongside yours, diving deep into knowns and unknowns, bringing unmatched technical proficiency and a consultative approach to study design and problem solving. Whether you seek to evaluate drug efficacy, study mechanism of action, identify potential adverse effects, or simply gather Pharmacokinetic/Pharmacodynamic (PK/PD) data, Certis offers the scientific, imaging and analytical horsepower to deliver actionable results.

Certis scientists have deep expertise in the most challenging PDX model development, including orthotopic intracranial and metastatic tumor models.

In vitro/ex vivo pharmacology

Certis offers a full suite of custom in vitro and ex vivo pharmacology services to support rapid screening and seamless translation from in vitro to in vivo studies.

  • Patient-derived xenograft (PDX) cell line development
  • Custom assay development
  • A whole array of cell viability/proliferation/cell cycle assays
  • High content screening using PDX cell lines and traditional cell lines
  • 96- or 384-well screenings
  • 2D/3D assays for phenotypic screening with flow cytometry
  • Cell-based lead screening
  • Biomarker identification

In vivo Pharmacology

Our scientists bring a whole new level of excellence to PDX development, custom in vivo study design and animal husbandry protocols.

  • Custom PDX model development
  • Tolerability and efficacy study design and execution with flexible options for dosing, frequency of formulation and imaging, in-life bleeds and measure-only extensions
  • Full necroscopy options including tissue collection, snap freezing, bone marrow collection, blood collection and optional processing as serum or plasma, Formalin-Fixed Paraffin-Embedded (FFPE)/Optimal Cutting Temperature (OCT) methods, time collection post-dosing, necropsy observations with photos, tissue measurements and weights

Tumor volume over time in response to standard of care agents.

Common Pharmacological Endpoints

  • Tumor volume measurements (TVM) over time compared to control group
  • Imaging and necropsy analysis of metastasis
  • Clinical observations in response to test agent dosages and vehicle composition
  • Overall survival and disease-free survival (Kaplan Meier Curves)
  • Identification of biomarkers and changes thereof
  • Tumor FFPE and custom histology and/or IHC
  • Spectral Flow Cytometric analysis of cell subpopulations in blood (on study) and/or post-takedown in other tissues
  • WES and RNAseq on study tumors

How can we help?

Contact Us

We may use “cookies,” log files, clear gifs or other technologies to help personalize your online experience. For example, a cookie can help us to recall your specific information on subsequent visits. Other technologies allow us to determine which email subscribers click through and read our newsletters. For more information see our Privacy Policy and Cookie Statement.

Close